We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.58B
AUM Growth
+$232M
Cap. Flow
+$52.5K
Cap. Flow %
0%
Top 10 Hldgs %
43.75%
Holding
149
New
7
Increased
20
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$60.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
VTRS icon
Viatris
VTRS
+$16.7M
4
MCK icon
McKesson
MCK
+$14.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$13.3M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$28.8M
2
MDCO
Medicines Co
MDCO
+$26.2M
3
INCY icon
Incyte
INCY
+$23.8M
4
ABT icon
Abbott
ABT
+$18.6M
5
CNC icon
Centene
CNC
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.08%
2 Real Estate 3.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRGO icon
101
Perrigo
PRGO
$1.43B
$2.48M 0.1%
37,300
– –
AXDX
102
DELISTED
Accelerate Diagnostics
AXDX
$2.42M 0.09%
10,000
-2,000
-17% -$457K
HZNP
103
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.41M 0.09%
162,900
– –
DBVT
104
DBV Technologies
DBVT
$817M
$2.31M 0.09%
6,560
– –
NSTG
105
DELISTED
NanoString Technologies, Inc.
NSTG
$2.25M 0.09%
+113,500
New +$2.16M
CDTX
106
DELISTED
Cidara Therapeutics
CDTX
$2.23M 0.09%
14,324
+7,700
+116% +$1.35M
HR
107
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.21M 0.09%
68,000
– –
BHC icon
108
Bausch Health
BHC
$2.25B
$2.12M 0.08%
192,000
– –
DPLO
109
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$2.08M 0.08%
130,223
– –
DVAX
110
DELISTED
Dynavax Technologies
DVAX
$2.05M 0.08%
345,050
– –
ORKA
111
Oruka Therapeutics
ORKA
$5.9B
$2.03M 0.08%
3,756
– –
CHRS icon
112
Coherus Oncology
CHRS
$227M
$1.9M 0.07%
90,000
– –
CYH icon
113
Community Health Systems
CYH
$391M
$1.81M 0.07%
203,935
– –
IPXL
114
DELISTED
Impax Laboratories, Inc.
IPXL
$1.57M 0.06%
124,335
– –
WELL icon
115
Welltower
WELL
$170B
$1.52M 0.06%
21,400
– –
HR icon
116
Healthcare Realty
HR
$7.46B
$1.45M 0.06%
46,000
– –
XLRN
117
DELISTED
Acceleron Pharma
XLRN
$1.44M 0.06%
54,450
– –
DOC icon
118
Healthpeak Properties
DOC
$15.2B
$1.42M 0.06%
45,500
– –
XENE icon
119
Xenon Pharmaceuticals
XENE
$6.2B
$1.4M 0.05%
350,000
-350,000
-50% -$2.75M
QURE icon
120
uniQure
QURE
$2.93B
$1.39M 0.05%
241,021
– –
ONCE
121
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.3M 0.05%
24,300
– –
JUNO
122
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.26M 0.05%
56,900
– –
GNMK
123
DELISTED
GenMark Diagnostics, Inc
GNMK
$1.2M 0.05%
93,349
– –
NTLA icon
124
Intellia Therapeutics
NTLA
$1.55B
$1.01M 0.04%
71,842
– –
ADYX
125
DELISTED
Adynxx Inc
ADYX
$833K 0.03%
27,500
– –
2 3 4
5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Tekla Capital Management held 149 positions worth $2.58B, up 9.9% from $2.35B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q1 2017 filing shows 7 new, 20 increased, 25 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M. The largest sale was Allergan plc, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2017 buy was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M.
  • Tekla Capital Management added most to Amgen in Q1 2017, an estimated $60.3M increase.
  • Tekla Capital Management's biggest Q1 2017 reduction was Allergan plc, cutting an estimated $28.8M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2017, selling an estimated $26.2M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.58B portfolio in Q1 2017.
  • Tekla Capital Management opened 7 new positions and closed 10 in Q1 2017.
  • Tekla Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.58B.

Based on Tekla Capital Management's 13F filing for Q1 2017, filed 12 May 2017.